• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
CAI Baole,MA Pengcheng.Protection of subjects in phase I clinical trials during normalized anti-epidemic period[J].Journal Of Pharmaceutical Research,2022,41(2):104-106[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 2409times   Download 2309次 QR Code for this article
Scan with your phone!
常态化抗疫期间Ⅰ期临床试验受试者保护
蔡宝乐,马鹏程
Font:Larger+|Default|Smaller-
(中国医学科学院皮肤病医院,江苏 南京 210002)
摘要:
新型冠状病毒肺炎的发生,给我国各行业都造成了巨大的影响,也对临床试验的顺利开展也带来了很多的困难。目前来看,长期抗疫已经不可避免,疫情期间开展临床试验已经成为常态。临床试验中,应该将保护受试者的安全放在首位。本文介绍中国医学科学院皮肤病医院I期临床在2020年5月至2020年12月开展的5个临床试验项目,通过试验前期、筛选期、试验期、清洗期、随访期采取的一系列措施,来保障受试者的安全,确保临床试验顺利的进行,试验数据和结果的可靠性、完整性。
关键词:  新型冠状病毒肺炎  Ⅰ期临床试验  受试者保护
DOI:10.13506/j.cnki.jpr.2022.02.008
基金项目:
Publication Date:February 25, 2022
Protection of subjects in phase I clinical trials during normalized anti-epidemic period
CAI Baole,MA Pengcheng
(Hospital for Skin Diseases,Chinese Academy of Medical Science,Nanjing 210002,China)
Abstract:
The occurrence of COVID-19 has great impact on various industries in China. It also brings a lot of difficulties to the smooth development of clinical trials. At present, long-term anti epidemic is inevitable, and clinical trials during the epidemic have become the norm. In clinical trials, the safety of subjects should be put in the first place.This paper introduces the five clinical trials carried out in the Hospital of Dermatology,Chinese Academy of Medical Sciences and Peking Union Medical College from May 2020 to December 2020,Through a series of measures taken in the early stage, screening period, test period, cleaning period and follow-up period, the safety of subjects is guaranteed, and the reliability and integrity of test data and results are ensured.
Key words:  COVID-19  Phase I clinical trial  Subject protection
Today's Visits:487    Total Visits:2383201
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.